Covid: German vaccine CureVac will be developed by Bayer too

Published by Laurent P. · Published on 7 January 2021 at 11h07 · Updated on 7 January 2021 at 12h58
The research for covid vaccine goes on… This Thursday January 7, pharmaceutical and agrochemical group Bayer announced they signed a partnership with laboratory CureVac to develop the ongoing vaccine. A vaccine that entered on December 14 the third clinical trial phase.

Good news in the research for Covid vaccine. Germany laboratory CureVac announced this Monday December 14, 2020 they are launching the last phase of the clinical trials for their candidate vaccine, joining the global race of pharmaceutical groups to develop an effective Covid-19 vaccine. “The first participant has been dosed in a Phase 2a clinical trial of its COVID-19 vaccine candidateCureVac announced this past September in a release when launching the phase 2 of the trials.

CureVac plans to initiate the global Phase 2b/3 clinical trial” the laboratory explained in the release. As for this new phase, “the first volunteer has been enrolled”. It is expected to be conducted on the larger scale than the previous one, including “over 35,000 participantsCureVac says, mainly from Europe and South America. A vaccine that uses – like Moderna and Pfizer do – the messenger RNA technology said to target elderly people first as they are more likely to get a severe form of the disease.

This Thursday January 7, 2021, pharmaceutical group Bayer stick its oar in saying they signed a partnerhsip with the laboratory to develop the vaccine. Both laboratories concluded - as a release reads - they "enter into a collaboration and services agreement / Bayer to support CureVac in numerous areas" including producing the Covid vaccine. The goal being: "to facilitate the supply of several hundred million doses".

Both companies added in the release that "Bayer will contribute its expertise and established infrastructure in areas such as clinical operations, regulatory affairs, pharmacovigilance, medical information, supply chain performance as well as support in selected countries.".

As for phase 2 of the clinical trials, it included 690 participants coming from Peru and Panama. “The start of the clinical Phase 2a trial in Peru and Panama represents an important step forward in our COVID-19 clinical study program,” Dr. Mariola Fotin-Mleczek, Chief Technology Officer of CureVac, said back in September.

If the vaccine passes all the test phases, it could be issued in 2021… A vaccine already secured by the European Commission that ordered 225 million doses. A new deal with the European Union, the fourth one since the pandemic broke out.

Practical information

Comments
Refine your search
Refine your search
Refine your search
Refine your search